natgillin/translations-raw huggingface dataset:
In an inhalation study in telemetered dogs, the cardiovascular system was a major target system for acute effects of Trimbow (increase in heart rate, decrease in blood pressure, ECG changes at higher doses), effects probably mainly related to the beta2-adrenergic activity of formoterol and the anti-muscarinic activity of glycopyrronium.
V inhalacijski študiji s telemetriranimi psi je bil kardiovaskularni sistem glavni ciljni sistem za akutne učinke zdravila Trimbow (zvišanje srčnega utripa, zmanjšanje krvnega tlaka, spremembe na EKG pri večjih odmerkih), kar so učinki, ki so najverjetneje v glavnem povezani z beta2 adrenergičnim delovanjem formoterola in antimuskarinskim delovanjem glikopironija.
A responder analysis showed that a significantly greater percentage of patients had a clinically significant improvement (focal score greater than or equal to 1) after 26 weeks with Trimbow than with a fixed combination of beclometasone dipropionate and formoterol (57.4% versus 51.8%; p = 0.027).
Analiza odzivnih bolnikov je pokazala, da je imel značilno večji odstotek bolnikov klinično pomembno izboljšanje (fokalni seštevek 1 ali več) po 26 tednih zdravljenja z zdravilom Trimbow v primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola (57,4 % v primerjavi z 51,8 %; p = 0,027).
Single dose pharmacokinetic data (see section 5.2) have demonstrated that in comparison to routine use without a spacer device, the use of Trimbow with the AeroChamber Plus spacer device increased the total systemic exposure (AUC0-t) to glycopyrronium.
Uporaba z nastavkom Farmakokinetični podatki po enkratnem odmerku (glejte poglavje 5.2) so pokazali, da je v primerjavi z redno uporabo brez nastavka uporaba zdravila Trimbow z nastavkom AeroChamber Plus povečala skupno sistemsko izpostavljenost (AUC0-t) glikopironiju.
This study also investigated the potential pharmacokinetic interaction between the active components of Trimbow by comparing the pharmacokinetic data obtained after a single dose of the extemporary combination or after a single dose of the single components beclometasone dipropionate/formoterol or glycopyrronium.
Ta študija je preučila tudi morebitne farmakokinetične interakcije med učinkovinami v zdravilu Trimbow na tak način, da je primerjala farmakokinetične podatke, pridobljene po enkratneme odmerku trojne kombinacije, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus glikopironija ali po enem odmerku posamičnih sestavin beklometazondipropionata /formoterola ali glikopironija.
If you forget to use Trimbow
Če ste pozabili uporabiti zdravilo Trimbow
The European Medicines Agency has waived the obligation to submit the results of studies with Trimbow in all subsets of the paediatric population in COPD (see section 4.2 for information on paediatric use).
Trimbow za vse podskupine pediatrične populacije s KOPB (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Trimbow is for inhalation use.
Zdravilo Trimbow se uporablja za inhaliranje.
It is preferable to avoid the use of Trimbow during labour due to the inhibitory effects of formoterol on uterine contractions.
Med rojevanjem se je uporabi zdravila Trimbow bolje izogniti zaradi zaviralnih učinkov formoterola na krčenje maternice.
There is no relevant use of Trimbow in the paediatric population (under 18 years of age) for the indication of COPD.
Zdravilo Trimbow ni namenjeno za uporabo pri pediatrični populaciji (pri otrocih, starih do 18 let) za indikacijo kronične obstruktivne pljučne bolezni (KOPB).
For beclometasone dipropionate, this results in a more potent effect than formulations with a non-extrafine particle size distribution (100 micrograms of beclometasone dipropionate extrafine in Trimbow are equivalent to 250 micrograms of beclometasone dipropionate in a non-extrafine formulation).
Beklometazondipropionat v obliki izredno majhnih delcev ima veliko močnejši učinek kot formulacije, kjer porazdelitev ni v obliki izredno majhnih delcev (100 mikrogramov beklometazondipropionata v obliki izredno majhnih delcev v zdravilu Trimbow ustreza 250 mikrogramom beklometazondipropionata v formulacijah, ki niso v obliki izredno majhnih delcev).
What Trimbow looks like and contents of the pack
Izgled zdravila Trimbow in vsebina pakiranja
Trimbow should be administered with caution in patients with active or quiescent pulmonary tuberculosis, fungal and viral infections in the airways.
Zdravilo Trimbow je treba pri bolnikih z aktivno ali mirujočo pljučno tuberkulozo ter glivično in virusno okužbo dihal uporabljati previdno.
How to use Trimbow
Kako uporabljati zdravilo Trimbow
If you are already using Trimbow
Če že uporabljate zdravilo Trimbow
Compared with tiotropium, Trimbow significantly improved IC by 39 mL (p = 0.025) and 60 mL (p = 0.001) after 26 and 52 weeks of treatment respectively.
V primerjavi s tiotropijem je zdravilo Trimbow značilno izboljšalo IC za 39 ml (p = 0,025) oz. 60 ml (p = 0,001) po 26 oz. 52 tednih zdravljenja.
After oral administration (40 to 80 micrograms), 6% to 10% of the dose was recovered in urine as unchanged active substance in healthy subjects; up to 8% of the dose was recovered as the glucuronide.
so pri zdravih prostovoljcih 6 % do 10 % odmerka potrdili v urinu v obliki nespremenjene učinkovine; do 8 % odmerka so potrdili v obliki glukuronida.
If you stop using Trimbow
Če ste prenehali uporabljati zdravilo Trimbow
Trimbow comes in a pressurised container (coated aluminium), with a metering valve.
Zdravilo Trimbow je na voljo v tlačnem vsebniku (obloženem z aluminijem) z odmernim ventilom.
Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution
Trimbow 87 mikrogramov/5 mikrogramov/9 mikrogramov inhalacijska raztopina pod tlakom
• Disulfiram, a medicine used in the treatment of people with alcoholism (drinking problems) or metronidazole, an antibiotic to treat infection in your body can cause side effects (e.g. feeling sick, being sick, stomach pain) due to the small amount of alcohol in Trimbow.
• disulfiram, zdravilom, ki se uporablja za zdravljenje ljudi z alkoholizmom ali metrodinazolom, antibiotikom za zdravljenje okužb v telesu lahko zaradi majhne količine alkohola v zdravilu
Trimbow is a pressurised inhalation, solution.
Zdravilo Trimbow je inhalacijska raztopina pod tlakom.
Study TRILOGY compared Trimbow with a fixed combination of beclometasone dipropionate and formoterol 100/6 micrograms two inhalations twice daily (1,368 randomised patients).
V študiji TRILOGY so primerjali zdravilo Trimbow s fiksno kombinacijo beklometazondipropionata in formoterola 100/6 mikrogramov, dve inhalaciji dvakrat na dan (1.368 randomiziranih bolnikov).
No differences were observed when comparing Trimbow and the extemporary triple combination made of a fixed combination of beclometasone dipropionate and formoterol plus tiotropium (difference of 3 mL in pre-dose FEV1 after 52 weeks of treatment).
V primerjavi zdravila Trimbow in trojne kombinacije, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus tiotropija, niso opazili razlik (razlika 3 ml v FEV1 pred odmerkom po 52 tednih zdravljenja).
Compared with a fixed combination of indacaterol and glycopyrronium, Trimbow improved average pre-dose FEV1 over the 52-week treatment period by 22 mL (p=0.018).
V primerjavi s fiksno kombinacijo indakaterola in glikopironija je zdravilo Trimbow izboljšalo povprečni FEV1 pred odmerkom po 52-tedenskem zdravljenju za 22 ml (p = 0,018).
Talk to your doctor or pharmacist before using Trimbow:
Pred začetkom uporabe zdravila Trimbow se posvetujte z zdravnikom ali farmacevtom:
Compared with tiotropium, Trimbow also reduced the rate of severe exacerbations (i.e. excluding moderate exacerbations) by 32% (rate: 0.067 versus 0.098 events per patient/year; p = 0.017).
V primerjavi s tiotropijem je zdravilo Trimbow zmanjšalo tudi stopnjo hudih poslabšanj (tj. brez zmernih poslabšanj) za 32 % (razmerje: 0,067 v primerjavi z 0,098 dogodka na bolnika/leto; p = 0,017).
Trimbow is used as a maintenance treatment for your COPD.
Zdravilo Trimbow se uporablja za vzdrževalno zdravljenje KOPB.
Related to Trimbow
V povezavi z zdravilom Trimbow
No differences were observed when comparing Trimbow with the extemporary triple combination made of beclometasone dipropionate and formoterol fixed combination plus tiotropium (moderate/severe exacerbation rate: 0.46 versus 0.45 events per patient/year).
V primerjavi zdravila Trimbow s trojno kombinacijo, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus tiotropija, niso opazili razlik (razmerje zmernih/hudih poslabšanj: 0,46 v primerjavi z 0,45 dogodka na bolnika/leto).
No differences were observed when comparing Trimbow and the extemporary triple combination made of fluticasone and vilanterol fixed combination plus tiotropium.
V primerjavi zdravila Trimbow in trojne kombinacije, sestavljene iz fiksne kombinacije flutikazona in vilanterola plus tiotropija ni bilo opaznih razlik.
Compared with tiotropium, Trimbow improved pre-dose FEV1 by 51 mL after 26 weeks of treatment and by 61 mL after 52 weeks of treatment.
V primerjavi s tiotropijem je zdravilo Trimbow izboljšalo FEV1 pred odmerkom za 51 ml po 26-tedenskem zdravljenju in za 61 ml po 52-tedenskem zdravljenju.
Simulations performed with a pharmacokinetic model showed that even when covariates had extreme values (body weight less than 40 kg and concomitant glomerular filtration rate below 27 mL/min/1.73 m²), exposure to Trimbow active substances remains in approximately a 2.5-fold range compared to the exposure in a typical patient with median covariate values.
(telesna masa manj kot 40 kg in sočasno stopnja glomerularne filtracije pod 27 ml/min/1,73 m²) izpostavljenost učinkovinam v zdravilu Trimbow ostala v razponu približno 2,5-kratnika v primerjavi z izpostavljenostjo običajnega bolnika z mediano vrednostjo sospremenljivk.
Study TRINITY compared Trimbow with tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily; in addition, effects were compared with an extemporary triple combination made of a fixed combination of beclometasone dipropionate and formoterol 100/6 micrograms two inhalations twice daily plus tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily (2,691 randomised patients).
18 mikrogramov praška za inhaliranje, trda kapsula, ena inhalacija enkrat na dan; poleg tega so učinke primerjali s trojno kombinacijo, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola 100/6 mikrogramov, dve inhalaciji dvakrat na dan, plus tiotropij 18 mikrogramov prašek za inhaliranje, trda kapsula, ena inhalacija enkrat na dan (2.691 randomiziranih bolnikov).
Use of Trimbow in patients with severe renal impairment or end-stage renal disease requiring dialysis, especially if associated with significant body weight reduction, should be considered only if the expected benefit outweighs the potential risk (see section 4.4 and section 5.2).
ki zahteva dializno zdravljenje, zlasti v povezavi s pomembnim zmanjšanjem telesne mase, je možna le, če so pričakovane koristi večje od možnih tveganj (glejte poglavje 4.4 in poglavje 5.2).
TRIBUTE was a 52-week activecontrolled study comparing Trimbow with a fixed combination of indacaterol/glycopyrronium 85/43 micrograms inhalation powder, hard capsule, one inhalation once daily (1,532 randomised patients).
52-tedenska študija, nadzorovana z učinkovino, v kateri so primerjali zdravilo Trimbow s fiksno kombinacijo indakaterola/glikopironija 85/43 mikrogramov prašek za inhaliranje, trda kapsula, ena inhalacija enkrat na dan (1.532 randomiziranih bolnikov).
Compared with a fixed combination of beclometasone dipropionate and formoterol, Trimbow significantly improved 2-hour post dose FEV1 by 117 mL after 26 weeks of treatment and by 103 mL after 52 weeks of treatment (p < 0.001).
V primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola je zdravilo Trimbow značilno izboljšalo FEV1 2 uri po odmerku za 117 ml po 26-tedenskem zdravljenju in za 103 ml po 52-tedenskem zdravljenju (p < 0,001).
Immediate hypersensitivity reactions have been reported after administration of Trimbow.
Preobčutljivost Po jemanju zdravila Trimbow so poročali o takojšnjih preobčutljivostnih reakcijah.
Compared with a fixed combination of beclometasone dipropionate and formoterol, Trimbow improved pre-dose FEV1 by 81 mL after 26 weeks of treatment and by 63 mL after 52 weeks of treatment.
V primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola je zdravilo Trimbow izboljšalo FEV1 pred odmerkom za 81 ml po 26-tedenskem zdravljenju in za 63 ml po 52-tedenskem zdravljenju.
Compared with a fixed combination of indacaterol and glycopyrronium, Trimbow reduced the rate of moderate/severe exacerbations over 52 weeks by 15% (rate: 0.50 versus 0.59 events per patient/year; p = 0.043).
V primerjavi s fiksno kombinacijo indakaterola in glikopironija je zdravilo Trimbow v 52 tednih zmanjšalo stopnjo zmernih/hudih poslabšanj za 15 % (razmerje: 0,50 v primerjavi z 0,59 dogodka na bolnika/leto; p = 0,043).
Compared with a fixed combination of beclometasone dipropionate and formoterol, Trimbow reduced the rate of moderate/severe exacerbations over 52 weeks by 23% (rate: 0.41 versus 0.53 events per patient/year; p = 0.005).
V primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola je zdravilo Trimbow v 52 tednih zmanjšalo stopnjo zmernih/hudih poslabšanj za 23 % (razmerje: 0,41 v primerjavi z 0,53 dogodka na bolnika/leto; p = 0,005).
If signs suggesting allergic reactions occur, in particular, angioedema (including difficulties in breathing or swallowing, swelling of the tongue, lips and face), urticaria or skin rash, Trimbow should be discontinued immediately and alternative therapy instituted.
oteklostjo jezika, ustnic in obraza), urtikarijo ali kožni izpuščaj, je treba uporabo zdravila Trimbow takoj prekiniti in uvesti drugo zdravljenje.
The study compared data obtained after treatment with a single dose of Trimbow (4 inhalations of 100/6/25 micrograms, a non-marketed formulation containing twice the approved strength of glycopyrronium) or a single dose of the extemporary combination of beclometasone dipropionate/formoterol (4 inhalations of 100/6 micrograms) plus glycopyrronium (4 inhalations of 25 micrograms).
100/6/25 mikrogramov, s formulacijo, ki je ni na trgu n ki vsebuje dvakratno odobreno jakost glikopironija) ali enkratnim odmerkom trojne kombinacije, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola 100/6 mikrogramov (4 inhalacije po 100/6 mikrogramov)
Compared with tiotropium, Trimbow reduced the rate of moderate/severe exacerbations over 52 weeks by 20% (rate: 0.46 versus 0.57 events per patient/year; p = 0.003).
V primerjavi s tiotropijem je zdravilo Trimbow v 52 tednih zmanjšalo stopnjo zmernih/hudih poslabšanj za 20 % (razmerje: 0,46 v primerjavi z 0,57 dogodka na bolnika/leto; p = 0,003).
TRISTAR was a 26-week active-controlled open label study comparing Trimbow with an extemporary combination made of a fixed combination of fluticasone/vilanterol 92/22 micrograms inhalation powder, one inhalation once daily plus tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily (1,157 randomised patients).
Trimbow s kombinacijo, sestavljeno iz fiksne kombinacije flutikazona/vilanterola 92/22 mikrogramov prašek za inhaliranje, ena inhalacija enkrat na dan plus tiotropij 18 mikrogramov prašek za inhaliranje, trda kapsula, ena inhalacija enkrat na dan (1.157 randomiziranih bolnikov).
Trimbow 87/5/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium
Trimbow 87/5/9 mikrogramov inhalacijska raztopina pod tlakom beklometazondipropionat/formoterolijev fumarat dihidrat/glikopironij
Trimbow significantly improved dyspnoea (measured as the Transition Dyspnoea Index - TDI - focal score) after 26 weeks of treatment compared with baseline (by 1.71 units; p < 0.001), but the adjusted mean difference versus a fixed combination of beclometasone dipropionate and formoterol was not statistically significant (0.21 units; p = 0.160).
p < 0,001), vendar prilagojena srednja razlika v primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola ni bila statistično značilna (0,21 enot; p = 0,160).
Trimbow should be used with caution in patients with cardiac arrhythmias, especially third degree atrioventricular block and tachyarrhythmias (accelerated and/or irregular heart beat), idiopathic subvalvular aortic stenosis, hypertrophic obstructive cardiomyopathy, severe heart disease (particularly acute myocardial infarction, ischaemic heart disease, congestive heart failure), occlusive vascular diseases (particularly arteriosclerosis), arterial hypertension and aneurysm.
idiopatsko subvalvularno aortno stenozo, hipertrofično obstruktivno kardiomiopatijo, hudo boleznijo srca (zlasti akutni miokardni infarkt, ishemična bolezen srca, kongestivno srčno popuščanje),
If you have been using a different inhaler containing beclometasone dipropionate previously, ask your doctor for advice, as the effective dose of beclometasone dipropionate in Trimbow for the treatment of COPD may be lower than that of some other inhalers.
saj je učinkoviti odmerek beklometazondipropionata v zdravilu Trimbow za zdravljenje KOPB morda manjši kot v nekaterih drugih inhalatorjih.
Contents of the pack and other information
Shranjevanje zdravila Trimbow Vsebina pakiranja in dodatne informacije
Package leaflet: Information for the user Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium
Navodilo za uporabo Trimbow 87 mikrogramov/5 mikrogramov/9 mikrogramov inhalacijska raztopina pod tlakom beklometazondipropionat/formoterolijev fumarat dihidrat/glikopironij
In addition, compared with both a fixed combination of beclometasone dipropionate and formoterol and with tiotropium, Trimbow significantly prolonged the time to first exacerbation (hazard ratio 0.80 and 0.84 respectively; p = 0.020 and 0.015 respectively), with no differences between Trimbow and the extemporary triple combination made of beclometasone dipropionate and formoterol fixed combination plus tiotropium (hazard ratio 1.06).
0,84; p = 0,020 oz. 0,015), brez razlik med zdravilom Trimbow in trojno kombinacijo, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus tiotropija (razmerje tveganja 1,06).
For glycopyrronium, the maximum plasma concentration was similar after administration of the fixed or extemporary combination, while the systemic exposure was slightly higher after administration of Trimbow than with the extemporary combination.
Za glikopironij je bila največja koncentracija v plazmi podobna po dajanju fiksne kombinacije ali trojne kombinacije, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus glikopironija,
It is important that you take your dose as advised by your doctor.
Če ste uporabili večji odmerek zdravila Trimbow, kot bi smeli Pomembno je, da uporabite odmerek, ki vam ga je svetoval zdravnik.
In patients with severe renal impairment, including those with end-stage renal disease requiring dialysis, especially if associated with a significant body weight reduction, Trimbow should be used only if the expected benefit outweighs the potential risk (see section 5.2).
Pri bolnikih s hudo okvaro ledvic, vključno s tistimi s končno ledvično odpovedjo, ki zahteva dializno zdravljenje, zlasti če je povezana s pomembnim zmanjšanjem telesne mase, se lahko zdravilo
The daily dose of Trimbow corresponds to a medium dose of inhaled corticosteroid; furthermore, these effects are much less likely to occur than with oral corticosteroids.
Ti učinki so bistveno manj verjetni med uporabo inhaliranih kortikosteroidov kot med uporabo peroralnih kortikosteroidov.
• trembling
Trimbow.
The combination of Trimbow with some other COPD medicines or medicines such as diuretics (medicines that make the body lose water, to treat heart disease or high blood pressure), can cause a sharp fall in your blood level of potassium.
Kombinacija zdravila Trimbow z nekaterimi drugimi zdravili za KOPB ali zdravili, kot so npr. diuretiki (zdravili za odvajanje vode,
How to store Trimbow
Shranjevanje zdravila Trimbow
2734 503 Barcarena Portugal
2734 503 Barcarena Portugalska
41470 Neuss Germany
41470 Neuss Nemčija
United Kingdom Janssen-Cilag Limited 50-100 Holmers Farm
Združeno kraljestvo Janssen-Cilag Limited 50-100 Holmers Farm
F-92787 Issy Les Moulineaux, Cedex 9 France
F-92787 Issy Les Moulineaux, Cedex 9 Francija
Vorgartenstraße 206B AT-1020 Vienna Austria
Vorgartenstraße 206B AT-1020 Vienna Avstrija
56 Eirinis Ave, Pefki Athens GR-151 21 Greece
56 Eirinis Ave, Pefki Athens GR-151 21 Grčija
56 Eirinis Ave, Pefki, Athens GR-151 21 Greece
56 Eirinis Ave, Pefki, Athens GR-151 21 Grčija
Intramuscular use; Intravenous use
Serenase intramuskularna uporaba, intravenska uporaba
Haldol oplossing voor injectie 5 mg/ml
Haldol oplossing voor injectie 5 mg/ml intramuskularna uporaba, intravenska uporaba
150 mg/15 ml 300mg/30ml
150 mg/15 ml 300mg/30ml peroralne kapljice, raztopina peroralna uporaba 10 mg/ml
Haldol-Janssen 5 mg/ml
Haldol-Janssen 5 mg/ml intramuskularna uporaba
This is normal.
To je povsem običajno.
Wait 30 minutes.
Počakajte 30 minut.
Absorption and distribution
Absorpcija in distribucija
The information above also applies to children and adolescents.
Zgoraj navedene informacije veljajo tudi na otroke in mladostnike.
Missed dose for 8 days or more
Zgrešeni odmerek 8 dni ali več
Call your healthcare provider immediately.
Takoj se obrnite na svojega zdravstvenega delavca.
• Kineret (which contains anakinra).
• Kineret (ki vsebuje anakinra).
Missed dose for up to 7 days
Pogrešani odmerek do 7 dni
a. Wash your hands with soap and water and dry them thoroughly.
a. Roke si umijte z milom in vodo ter jih dobro posušite.
You may inject into:
Zdravilo si lahko injicirate v:
No data are available.
Trenutno ni na voljo nobenih podatkov.
(furunculosis)
(furunkuloza)
b. If you do not have an approved sharps disposal container, you may use a household container that is:
b. Če nimate na voljo odobrenega vsebnika za ostre odpadke, lahko uporabite vsebnik za gospodinjske odpadke, ki:
• properly labelled to warn of hazardous waste inside the container.
• je ustrezno označen, da vsebuje nevarne odpadke.
Always have the outer carton of the medicine with you, even if it is empty.
S seboj imejte vedno zunanjo ovojnino zdravila, tudi če je prazna.
Periodic skin examination is recommended, particularly for patients with risk factors for skin cancer.
Priporočljivo je periodično pregledovanje kože, predvsem za bolnike z dejavniki tveganja za kožnega raka.
Note: If the olive green plunger rod does not fill the window completely, you did not receive your full dose.
Opomba: Če olivno zelen bat brizge ni viden v celotnem okencu, niste prejeli celotnega odmerka.
• you are allergic to infliximab or any of the other ingredients of this medicine (listed in section 6),
• če ste alergični na infliksimab ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
a. Prepare a clean, flat surface, such as a table or countertop, in a well-lit area.
a. Pripravite čisto ravno površino, npr. mizo ali pult, na dobro osvetljenem mestu.
• Ask your healthcare provider how often you will need to give an injection.
• Zdravstvenega delavca vprašajte, kako pogosto boste morali izvajati injiciranje.
1 vial 2 vials 3 vials 4 vials 5 vials
1 viala 2 viali 3 viale 4 viale 5 vial
Patients with a PGA score ≥3 were eligible to receive an additional infusion of the same treatment at week 26.
Bolniki z oceno PGA ≥ 3 so lahko prejeli dodatno infuzijo iste terapije v 26. tednu.
c. When your sharps disposal container is almost full, it should be disposed of in accordance with local requirements.
c. Ko je vsebnik za ostre odpadke skoraj poln, ga zavrzite skladno z lokalnimi zahtevami.
For study details, see Section 5.1.
Za več podrobnosti o študiji glejte poglavje 5.1.